Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.06 | 0.03 |
| FCF Yield | -41.56% | -28.64% | -18.39% | -16.83% |
| EV / EBITDA | -2.33 | -2.43 | -4.84 | -5.16 |
| Quality | ||||
| ROIC | -11.40% | -13.64% | -12.93% | -12.89% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 1.01 | 1.29 | 0.68 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,994,891.64% | 2,994,891.64% | 2,994,891.64% | 4,070,017.86% |
| Free Cash Flow Growth | -6.35% | 17.80% | 9.86% | -24.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.00 | 0.07 | -0.12 | -0.04 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,091.94 | -2,668.74 | -2,094.98 | -2,299.63 |